Sunday, 26 August 2018

Novartis's Kymriah wins EU approval for blood cancer treatment

Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah, its CAR-T cell therapy, to treat children with a form of leukemia and adults with lymphoma.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)